<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20231113131019&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20231113131019&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Mon, 13 Nov 2023 18:10:21 +0000</lastbuilddate>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4776. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To compare clinical characteristics and treatment outcomes of torsemide vs furosemide in patients hospitalized with de novo HF vs WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: All patients with a documented ejection fraction who were randomized in the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) trial, conducted from June 18 through March 2022, were included in this post hoc analysis. Study data were analyzed March to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Patients were categorized by HF type and further divided by loop diuretic strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: End points included all-cause mortality and hospitalization outcomes over 12 months, as well as change from baseline in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 2858 patients (mean [SD] age, 64.5 [14.0] years; 1803 male [63.1%]), 838 patients (29.3%) had de novo HF, and 2020 patients (70.7%) had WHF. Patients with de novo HF were younger (mean [SD] age, 60.6 [14.5] years vs 66.1 [13.5] years), had a higher glomerular filtration rate (mean [SD], 68.6 [24.9] vs 57.0 [24.0]), lower levels of natriuretic peptides (median [IQR], brain-type natriuretic peptide, 855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL), and tended to be discharged on lower doses of loop diuretic (mean [SD], 50.3 [46.2] mg vs 63.8 [52.4] mg). De novo HF was associated with lower all-cause mortality at 12 months (de novo, 65 of 838 [9.1%] vs WHF, 408 of 2020 [25.4%]; adjusted hazard ratio [aHR], 0.50; 95% CI, 0.38-0.66; P &lt; .001). Similarly, lower all-cause first rehospitalization at 12 months and greater improvement from baseline in KCCQ-CSS at 12 months were noted among patients with de novo HF (median [IQR]: de novo, 29.94 [27.35-32.54] vs WHF, 23.68 [21.62-25.74]; adjusted estimated difference in means: 6.26; 95% CI, 3.72-8.81; P &lt; .001). There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient-years]: torsemide, 27 [7.4%] vs furosemide, 38 [10.9%]; aHR, 0.70; 95% CI, 0.40-1.14; P = .15) or WHF (torsemide 212 [26.8%] vs furosemide, 196 [24.0%]; aHR, 1.08; 95% CI, 0.89-1.32; P = .42; P for interaction = .10), In addition, no significant differences in hospitalizations, first all-cause hospitalization, or total hospitalizations at 12 months were noted with a strategy of torsemide vs furosemide in either de novo HF or WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955908</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4776>10.1001/jamacardio.2023.4776</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955908</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Selim R Krim</dc:creator>
<dc:creator>Senthil Anand</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Anqi Chen</dc:creator>
<dc:creator>Daniel Wojdyla</dc:creator>
<dc:creator>Juan Vilaro</dc:creator>
<dc:creator>Herbert Haught</dc:creator>
<dc:creator>John M Herre</dc:creator>
<dc:creator>Eric L Eisenstein</dc:creator>
<dc:creator>Kevin J Anstrom</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37955908</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4776</dc:identifier>
</item>
<item>
<title>Neighborhood Environmental Burden and Cardiovascular Health in the US</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this cross-sectional study of US neighborhoods, cumulative environmental burden was associated with higher rates of cardiovascular risk factors and diseases, although absolute differences were small. The strongest associations were observed in socially vulnerable neighborhoods. Whether initiatives that address poor environmental conditions will improve cardiovascular health requires additional prospective investigations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4680. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiovascular disease is the leading cause of death in the US. However, little is known about the association between cumulative environmental burden and cardiovascular health across US neighborhoods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association of neighborhood-level environmental burden with prevalence of cardiovascular risk factors and diseases, overall and by levels of social vulnerability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTINGS, AND PARTICIPANTS: This was a national cross-sectional study of 71 659 US Census tracts. Environmental burden (EBI) and social vulnerability indices from the US Centers for Disease Control and Prevention (CDC) and Agency for Toxic Substances and Disease Registry were linked to the 2020 CDC PLACES data set. Data were analyzed from March to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: The EBI, a measure of cumulative environmental burden encompassing 5 domains (air pollution, hazardous or toxic sites, built environment, transportation infrastructure, and water pollution).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Neighborhood-level prevalence of cardiovascular risk factors (hypertension, diabetes, and obesity) and cardiovascular diseases (coronary heart disease and stroke).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Across the US, neighborhoods with the highest environmental burden (top EBI quartile) were more likely than those with the lowest environmental burden (bottom EBI quartile) to be urban (16 626 [92.7%] vs 13 414 [75.4%]), in the Midwest (5191 [28.9%] vs 2782 [15.6%]), have greater median (IQR) social vulnerability scores (0.64 [0.36-0.85] vs 0.42 [0.20-0.65]), and have higher proportions of adults in racial or ethnic minority groups (median [IQR], 34% [12-73] vs 12% [5-30]). After adjustment, neighborhoods with the highest environmental burden had significantly higher rates of cardiovascular risk factors than those with the lowest burden, including hypertension (mean [SD], 32.83% [7.99] vs 32.14% [6.99]; adjusted difference, 0.84%; 95% CI, 0.71-0.98), diabetes (mean [SD], 12.19% [4.33] vs 10.68% [3.27]; adjusted difference, 0.62%; 95% CI, 0.53-0.70), and obesity (mean [SD], 33.57% [7.62] vs 30.86% [6.15]; adjusted difference, 0.77%; 95% CI, 0.60-0.94). Similarly, neighborhoods with the highest environmental burden had significantly higher rates of coronary heart disease (mean [SD], 6.66% [2.15] vs 6.82% [2.41]; adjusted difference, 0.28%; 95% CI, 0.22-0.33) and stroke (mean [SD], 3.65% [1.47] vs 3.31% [1.12]; adjusted difference, 0.19%; 95% CI, 0.15-0.22). Results were consistent after matching highest and lowest environmentally burdened neighborhoods geospatially and based on other covariates. The associations between environmental burden quartiles and cardiovascular risk factors and diseases were most pronounced among socially vulnerable neighborhoods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cross-sectional study of US neighborhoods, cumulative environmental burden was associated with higher rates of cardiovascular risk factors and diseases, although absolute differences were small. The strongest associations were observed in socially vulnerable neighborhoods. Whether initiatives that address poor environmental conditions will improve cardiovascular health requires additional prospective investigations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955891</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4680>10.1001/jamacardio.2023.4680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955891</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Michael Liu</dc:creator>
<dc:creator>Vishal R Patel</dc:creator>
<dc:creator>Renee N Salas</dc:creator>
<dc:creator>Mary B Rice</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>ZhaoNian Zheng</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Neighborhood Environmental Burden and Cardiovascular Health in the US</dc:title>
<dc:identifier>pmid:37955891</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4680</dc:identifier>
</item>
<item>
<title>Prioritizing the Exposome to Reduce Cardiovascular Disease Burden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4722. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955872</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4722>10.1001/jamacardio.2023.4722</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955872</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Kai Chen</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Prioritizing the Exposome to Reduce Cardiovascular Disease Burden</dc:title>
<dc:identifier>pmid:37955872</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4722</dc:identifier>
</item>
<item>
<title>Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955620</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067588>10.1161/CIRCULATIONAHA.123.067588</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955620</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>David J Whellan</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume</dc:title>
<dc:identifier>pmid:37955620</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067588</dc:identifier>
</item>
<item>
<title>Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Background: Physical activity is pivotal in managing heart failure with reduced ejection fraction (HFrEF), and walking integrated into daily life is an especially suitable form of such physical activity. This study aimed to determine if a 6-month lifestyle walking intervention combining self-monitoring and regular phone counseling improves functional capacity assessed by the six-minute walk test (6MWT) in stable patients with HFrEF compared to usual care. Methods: The WATCHFUL trial was a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Physical activity is pivotal in managing heart failure with reduced ejection fraction (HFrEF), and walking integrated into daily life is an especially suitable form of such physical activity. This study aimed to determine if a 6-month lifestyle walking intervention combining self-monitoring and regular phone counseling improves functional capacity assessed by the six-minute walk test (6MWT) in stable patients with HFrEF compared to usual care. <b>Methods:</b> The WATCHFUL trial was a 6-month, multicenter, parallel-group, randomized, controlled trial recruiting HFrEF patients from six Czech cardiovascular centers. Eligible participants were ≥18 years old with left ventricular ejection fraction &lt;40% and NYHA class II/III symptoms, on guidelines-recommended medication, excluding those exceeding 450m in the baseline 6MWT. Patients in the intervention group were equipped with a Garmin vívofit activity tracker and received monthly phone counseling from research nurses who encouraged them to employ behavior change techniques such as self-monitoring, goal-setting, and action planning to increase their daily step count. The control group patients continued usual care. The primary outcome was the difference between groups in the distance (in meters) walked during the 6MWT at 6 months. Secondary outcomes included daily step count and minutes of moderate-to-vigorous physical activity (MVPA) as measured by the hip-worn Actigraph wGT3X-BT accelerometer, NT-proBNP and hsCRP biomarkers, ejection fraction, anthropometric measures, depression score, self-efficacy, quality of life, and survival risk score. The primary analysis was conducted by intention-to-treat. <b>Results:</b> From 218 screened patients, 202 were randomized (65 years; 22.8% female; 90.6% NYHA II; left ventricular ejection fraction 32.5%; 6MWT 385m; 5071 steps/day; 10.9 minutes of MVPA per day). At six months, no between-group differences were detected for the 6MWT (7.4 m, 95% CI -8.0 to 22.7, p=0.345, N=186). The intervention group increased their average daily step count by 1420 (95% CI: 749; 2091) and daily minutes of MVPA by 8.2 (95% CI: 3.0; 13.3) over the control group. No between-group differences were detected for any other secondary outcomes. <b>Conclusions:</b> While the lifestyle intervention in patients with HFrEF improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity. Further research is needed to understand the disconnect between increased physical activity and functional outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955615</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067395>10.1161/CIRCULATIONAHA.123.067395</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955615</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Tomas Vetrovsky</dc:creator>
<dc:creator>Michal Siranec</dc:creator>
<dc:creator>Tereza Frybova</dc:creator>
<dc:creator>Iulian Gant</dc:creator>
<dc:creator>Iveta Svobodova</dc:creator>
<dc:creator>Ales Linhart</dc:creator>
<dc:creator>Jiri Parenica</dc:creator>
<dc:creator>Marie Miklikova</dc:creator>
<dc:creator>Lenka Sujakova</dc:creator>
<dc:creator>David Pospisil</dc:creator>
<dc:creator>Radek Pelouch</dc:creator>
<dc:creator>Daniela Odrazkova</dc:creator>
<dc:creator>Petr Parizek</dc:creator>
<dc:creator>Jan Precek</dc:creator>
<dc:creator>Martin Hutyra</dc:creator>
<dc:creator>Milos Taborsky</dc:creator>
<dc:creator>Jiri Vesely</dc:creator>
<dc:creator>Martin Griva</dc:creator>
<dc:creator>Miroslav Semerad</dc:creator>
<dc:creator>Vaclav Bunc</dc:creator>
<dc:creator>Karolina Hrabcova</dc:creator>
<dc:creator>Adela Vojkuvkova</dc:creator>
<dc:creator>Michal Svoboda</dc:creator>
<dc:creator>Jan Belohlavek</dc:creator>
<dc:creator>WATCHFUL Investigators</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial</dc:title>
<dc:identifier>pmid:37955615</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067395</dc:identifier>
</item>
<item>
<title>Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Background: Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. Methods: This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Parent Heart Watch database...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.065908. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. <b>Methods:</b> This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Parent Heart Watch database and media reports, National Center for Catastrophic Sports Injury Research database, and insurance claims). Autopsy reports and medical history were reviewed by an expert panel to adjudicate causes of SCD. <b>Results:</b> A total of 143 SCD cases in National Collegiate Athletic Association athletes were identified from 1102 total deaths. The National Collegiate Athletic Association resolutions list identified 117 of 143 (82%), the Parent Heart Watch database or media reports identified 89 of 143 (62%), the National Center for Catastrophic Sports Injury Research database identified 63 of 143 (44%), and insurance claims identified 27 of 143 (19%) SCD cases. The overall incidence of SCD was 1:63682 athlete-years (95% CI, 1:54065-1:75010). Incidence was higher in male athletes than in female athletes (1:43348 [95% CI, 1:36228-1:51867] versus 1:164504 [95% CI, 1:110552-1:244787] athlete-years, respectively) and Black athletes compared with White athletes (1:26704 [1:20417-1:34925] versus 1:74581 [1:60247-1:92326] athlete-years, respectively). The highest incidence of SCD was among Division I male basketball players (1:8188 [White, 1:5848; Black, 1:7696 athlete-years]). The incidence rate for SCD decreased over the study period (5-year incidence rate ratio, 0.71 [95% CI, 0.61-0.82]), whereas the rate of noncardiovascular deaths remained stable (5-year incidence rate ratio, 0.98 [95% CI, 0.94-1.04]). Autopsy-negative sudden unexplained death (19.5%) was the most common postmortem examination finding, followed by idiopathic left ventricular hypertrophy or possible cardiomyopathy (16.9%) and hypertrophic cardiomyopathy (12.7%), in cases with enough information for adjudication (118 of 143). Eight cases of death were attributable to myocarditis over the study period (1 case from January 1, 2020, through June 30, 2022), with none attributed to COVID-19 infection. SCD events were exertional in 50% of cases. Exertional SCD was more common among those with coronary artery anomalies (100%) and arrhythmogenic cardiomyopathy (83%). <b>Conclusions:</b> The incidence of SCD in college athletes has decreased. Male sex, Black race, and basketball are associated with a higher incidence of SCD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955565</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065908>10.1161/CIRCULATIONAHA.123.065908</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955565</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bradley J Petek</dc:creator>
<dc:creator>Timothy W Churchill</dc:creator>
<dc:creator>Nathaniel Moulson</dc:creator>
<dc:creator>Stephanie A Kliethermes</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Jonathan A Drezner</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Kristen L Kucera</dc:creator>
<dc:creator>David M Siebert</dc:creator>
<dc:creator>Lauren Salerno</dc:creator>
<dc:creator>Monica Zigman Suchsland</dc:creator>
<dc:creator>Irfan M Asif</dc:creator>
<dc:creator>Joseph J Maleszewski</dc:creator>
<dc:creator>Kimberly G Harmon</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study</dc:title>
<dc:identifier>pmid:37955565</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065908</dc:identifier>
</item>
<item>
<title>Declining Risk of Sudden Cardiac Death in Young Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067243. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067243>10.1161/CIRCULATIONAHA.123.067243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955558</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Domenico Corrado</dc:creator>
<dc:creator>Alessandro Zorzi</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Declining Risk of Sudden Cardiac Death in Young Athletes</dc:title>
<dc:identifier>pmid:37955558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067243</dc:identifier>
</item>
<item>
<title>Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.122.321836. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pulmonary hypertension (PH) is a chronic vascular disease characterized, among other abnormalities, by hyperproliferative smooth muscle cells and a perturbed cellular redox and metabolic balance. Oxidants induce cell cycle arrest to halt proliferation; however, little is known about the redox-regulated effector proteins that mediate these processes. Here, we report a novel kinase-inhibitory disulfide bond in cyclin D-CDK4 (cyclin-dependent kinase 4) and investigate its role in cell proliferation and PH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Oxidative modifications of cyclin D-CDK4 were detected in human pulmonary arterial smooth muscle cells and human pulmonary arterial endothelial cells. Site-directed mutagenesis, tandem mass-spectrometry, cell-based experiments, in vitro kinase activity assays, in silico structural modeling, and a novel redox-dead constitutive knock-in mouse were utilized to investigate the nature and definitively establish the importance of CDK4 cysteine modification in pulmonary vascular cell proliferation. Furthermore, the cyclin D-CDK4 oxidation was assessed in vivo in the pulmonary arteries and isolated human pulmonary arterial smooth muscle cells of patients with pulmonary arterial hypertension and in 3 preclinical models of PH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide dimer between C7/8 and C135, respectively, in cells in vitro and in pulmonary arteries in vivo to inhibit cyclin D-CDK4 kinase activity, decrease Rb (retinoblastoma) protein phosphorylation, and induce cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, which decreases cell proliferation rate and alleviates disease phenotype in an experimental mouse PH model, suggesting this cysteine is indispensable for cyclin D-CDK4 kinase activity. Pulmonary arteries and human pulmonary arterial smooth muscle cells from patients with pulmonary arterial hypertension display a decreased level of CDK4 disulfide, consistent with CDK4 being hyperactive in human pulmonary arterial hypertension. Furthermore, auranofin treatment, which induces the cyclin D-CDK4 disulfide, attenuates disease severity in experimental PH models by mitigating pulmonary vascular remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955182</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.321836>10.1161/CIRCRESAHA.122.321836</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955182</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Hannah Knight</dc:creator>
<dc:creator>Giancarlo Abis</dc:creator>
<dc:creator>Manpreet Kaur</dc:creator>
<dc:creator>Hannah L H Green</dc:creator>
<dc:creator>Susanne Krasemann</dc:creator>
<dc:creator>Kristin Hartmann</dc:creator>
<dc:creator>Steven Lynham</dc:creator>
<dc:creator>James Clark</dc:creator>
<dc:creator>Lan Zhao</dc:creator>
<dc:creator>Clemens Ruppert</dc:creator>
<dc:creator>Astrid Weiss</dc:creator>
<dc:creator>Ralph T Schermuly</dc:creator>
<dc:creator>Philip Eaton</dc:creator>
<dc:creator>Olena Rudyk</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation</dc:title>
<dc:identifier>pmid:37955182</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.321836</dc:identifier>
</item>
<item>
<title>DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14^(Δ/Δ) mice, by reducing abnormal S/ER clusters.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.123.323304. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The p.Arg14del variant of the <i>PLN</i> (phospholamban) gene causes cardiomyopathy, leading to severe heart failure. Calcium handling defects and perinuclear PLN aggregation have both been suggested as pathological drivers of this disease. Dwarf open reading frame (DWORF) has been shown to counteract PLN regulatory calcium handling function in the sarco/endoplasmic reticulum (S/ER). Here, we investigated the potential disease-modulating action of DWORF in this cardiomyopathy and its effects on calcium handling and PLN aggregation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We studied a PLN-R14del mouse model, which develops cardiomyopathy with similar characteristics as human patients, and explored whether cardiac DWORF overexpression could delay cardiac deterioration. To this end, R14<sup>Δ/Δ</sup> (homozygous PLN-R14del) mice carrying the DWORF transgene (R14<sup>Δ/Δ</sup>DWORF<sup>Tg</sup> [R14<sup>Δ/Δ</sup> mice with a copy of the DWORF transgene]) were used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: DWORF expression was suppressed in hearts of R14<sup>Δ/Δ</sup> mice with severe heart failure. Restoration of DWORF expression in R14<sup>Δ/Δ</sup> mice delayed cardiac fibrosis and heart failure and increased life span >;2-fold (from 8 to 18 weeks). DWORF accelerated sarcoplasmic reticulum calcium reuptake and relaxation in isolated cardiomyocytes with wild-type PLN, but in R14<sup>Δ/Δ</sup> cardiomyocytes, sarcoplasmic reticulum calcium reuptake and relaxation were already enhanced, and no differences were detected between R14<sup>Δ/Δ</sup> and R14<sup>Δ/Δ</sup>DWORF<sup>Tg</sup>. Rather, DWORF overexpression delayed the appearance and formation of large pathogenic perinuclear PLN clusters. Careful examination revealed colocalization of sarcoplasmic reticulum markers with these PLN clusters in both R14<sup>Δ/Δ</sup> mice and human p.Arg14del PLN heart tissue, and hence these previously termed aggregates are comprised of abnormal organized S/ER. This abnormal S/ER organization in PLN-R14del cardiomyopathy contributes to cardiomyocyte cell loss and replacement fibrosis, consequently resulting in cardiac dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14<sup>Δ/Δ</sup> mice, by reducing abnormal S/ER clusters.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955153</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323304>10.1161/CIRCRESAHA.123.323304</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955153</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nienke M Stege</dc:creator>
<dc:creator>Tim R Eijgenraam</dc:creator>
<dc:creator>Vivian Oliveira Nunes Teixeira</dc:creator>
<dc:creator>Anna M Feringa</dc:creator>
<dc:creator>Elisabeth M Schouten</dc:creator>
<dc:creator>Diederik W D Kuster</dc:creator>
<dc:creator>Jolanda van der Velden</dc:creator>
<dc:creator>Anouk H G Wolters</dc:creator>
<dc:creator>Ben N G Giepmans</dc:creator>
<dc:creator>Catherine A Makarewich</dc:creator>
<dc:creator>Rhonda Bassel-Duby</dc:creator>
<dc:creator>Eric N Olson</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Herman H W Silljé</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</dc:title>
<dc:identifier>pmid:37955153</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323304</dc:identifier>
</item>
<item>
<title>NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.122.322244. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure, characterized by cardiac remodeling, is associated with abnormal epigenetic processes and aberrant gene expression. Here, we aimed to elucidate the effects and mechanisms of NAT10 (N-acetyltransferase 10)-mediated N4-acetylcytidine (ac4C) acetylation during cardiac remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: NAT10 and ac4C expression were detected in both human and mouse subjects with cardiac remodeling through multiple assays. Subsequently, acetylated RNA immunoprecipitation and sequencing, thiol (SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq), and ribosome sequencing (Ribo-seq) were employed to elucidate the role of ac4C-modified posttranscriptional regulation in cardiac remodeling. Additionally, functional experiments involving the overexpression or knockdown of NAT10 were conducted in mice models challenged with Ang II (angiotensin II) and transverse aortic constriction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NAT10 expression and RNA ac4C levels were increased in in vitro and in vivo cardiac remodeling models, as well as in patients with cardiac hypertrophy. Silencing and inhibiting NAT10 attenuated Ang II-induced cardiomyocyte hypertrophy and cardiofibroblast activation. Next-generation sequencing revealed ac4C changes in both mice and humans with cardiac hypertrophy were associated with changes in global mRNA abundance, stability, and translation efficiency. Mechanistically, NAT10 could enhance the stability and translation efficiency of <i>CD47</i> and <i>ROCK2</i> transcripts by upregulating their mRNA ac4C modification, thereby resulting in an increase in their protein expression during cardiac remodeling. Furthermore, the administration of Remodelin, a NAT10 inhibitor, has been shown to prevent cardiac functional impairments in mice subjected to transverse aortic constriction by suppressing cardiac fibrosis, hypertrophy, and inflammatory responses, while also regulating the expression levels of CD47 and ROCK2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37955115</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.322244>10.1161/CIRCRESAHA.122.322244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955115</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jing Shi</dc:creator>
<dc:creator>Chuanxi Yang</dc:creator>
<dc:creator>Kun Zhao</dc:creator>
<dc:creator>Jing Zhang</dc:creator>
<dc:creator>Peng Li</dc:creator>
<dc:creator>Chuiyu Kong</dc:creator>
<dc:creator>Xiaoguang Wu</dc:creator>
<dc:creator>Haoliang Sun</dc:creator>
<dc:creator>Rui Zheng</dc:creator>
<dc:creator>Wei Sun</dc:creator>
<dc:creator>Lianmin Chen</dc:creator>
<dc:creator>Xiangqing Kong</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</dc:title>
<dc:identifier>pmid:37955115</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.322244</dc:identifier>
</item>
<item>
<title>Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone all individually reduce cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known. Methods: We used data from 2 SGLT2i trials (CANVAS and CREDENCE), 2 non-steroidal MRA trials...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067584. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Sodium glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone all individually reduce cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known. <b>Methods:</b> We used data from 2 SGLT2i trials (CANVAS and CREDENCE), 2 non-steroidal MRA trials (FIDELIO-DKD and FIGARO-DKD) and 8 GLP-1 RA trials to estimate the relative effects of combination therapy versus conventional care (renin-angiotensin system blockade and traditional risk factor control) on cardiovascular, kidney and mortality outcomes. Using actuarial methods, we then estimated absolute risk reductions with combination SGLT2i, GLP-1 RA and non-steroidal MRA in patients with type 2 diabetes and at lease moderately increased albuminuria (urinary albumin:creatinine ratio ≥30 mg/g) by applying estimated combination treatment effects to participants receiving conventional care in CANVAS and CREDENCE. <b>Results:</b> Compared to conventional care, combination SGLT2i, GLP-1 RA and non-steroidal MRA was associated with a hazard ratio of 0.65 (95% CI 0.55-0.76) for major adverse cardiovascular events (MACE; nonfatal myocardial infarction, nonfatal stroke or cardiovascular death). The corresponding estimated absolute risk reduction over 3 years was 4.4% (95% CI 3.0-5.7) with a number-needed-to-treat of 23 (95% CI 18-33). For a 50-year-old commencing combination therapy, estimated MACE event-free survival was 21.1 years compared to 17.9 years for conventional care (3.2 years gained, 95% CI 2.1-4.3). There were also projected gains in survival free from hospitalized heart failure (3.2 years, 95% CI 2.4-4.0), CKD progression (5.5 years, 95% CI 4.0-6.7), cardiovascular death (2.2 years, 95% CI 1.2-3.0) and all-cause death (2.4 years, 95% CI 1.4-3.4). Attenuated but clinically relevant gains in event-free survival were observed in analyses assuming 50% additive effects of combination therapy, including for MACE (2.4 years, 95% CI 1.1-3.5), CKD progression (4.5 years, 95% CI 2.8-5.9),) and all-cause death (1.8 years, 95% CI 0.7-2.8). <b>Conclusions:</b> In patients with type 2 diabetes and at least moderately increased albuminuria, combination treatment with SGLT2i, GLP-1 RA and non-steroidal MRA has the potential to afford relevant gains in cardiovascular and kidney event-free and overall survival.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952217</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067584>10.1161/CIRCULATIONAHA.123.067584</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952217</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Hiddo J L Heerspink</dc:creator>
<dc:creator>Priya Vart</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Robert A Fletcher</dc:creator>
<dc:creator>Clare Arnott</dc:creator>
<dc:creator>Juliana de Oliveira Costa</dc:creator>
<dc:creator>Michael O Falster</dc:creator>
<dc:creator>Sallie-Anne Pearson</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Bruce Neal</dc:creator>
<dc:creator>Rajiv Agarwal</dc:creator>
<dc:creator>George Bakris</dc:creator>
<dc:creator>Vlado Perkovic</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria</dc:title>
<dc:identifier>pmid:37952217</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067584</dc:identifier>
</item>
<item>
<title>Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: CHIP may represent a novel risk factor for incident arrhythmias, indicating a potential target for modulation towards arrhythmia prevention and treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 11:ehad670. doi: 10.1093/eurheartj/ehad670. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Clonal haematopoiesis of indeterminate potential (CHIP), the age-related expansion of blood cells with preleukemic mutations, is associated with atherosclerotic cardiovascular disease and heart failure. This study aimed to test the association of CHIP with new-onset arrhythmias.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: UK Biobank participants without prevalent arrhythmias were included. Co-primary study outcomes were supraventricular arrhythmias, bradyarrhythmias, and ventricular arrhythmias. Secondary outcomes were cardiac arrest, atrial fibrillation, and any arrhythmia. Associations of any CHIP [variant allele fraction (VAF) ≥ 2%], large CHIP (VAF ≥10%), and gene-specific CHIP subtypes with incident arrhythmias were evaluated using multivariable-adjusted Cox regression. Associations of CHIP with myocardial interstitial fibrosis [T1 measured using cardiac magnetic resonance (CMR)] were also tested.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 410 702 participants [CHIP: n = 13 892 (3.4%); large CHIP: n = 9191 (2.2%)]. Any and large CHIP were associated with multi-variable-adjusted hazard ratios of 1.11 [95% confidence interval (CI) 1.04-1.18; P = .001] and 1.13 (95% CI 1.05-1.22; P = .001) for supraventricular arrhythmias, 1.09 (95% CI 1.01-1.19; P = .031) and 1.13 (95% CI 1.03-1.25; P = .011) for bradyarrhythmias, and 1.16 (95% CI, 1.00-1.34; P = .049) and 1.22 (95% CI 1.03-1.45; P = .021) for ventricular arrhythmias, respectively. Associations were independent of coronary artery disease and heart failure. Associations were also heterogeneous across arrhythmia subtypes and strongest for cardiac arrest. Gene-specific analyses revealed an increased risk of arrhythmias across driver genes other than DNMT3A. Large CHIP was associated with 1.31-fold odds (95% CI 1.07-1.59; P = .009) of being in the top quintile of myocardial fibrosis by CMR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CHIP may represent a novel risk factor for incident arrhythmias, indicating a potential target for modulation towards arrhythmia prevention and treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952204</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad670>10.1093/eurheartj/ehad670</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952204</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Art Schuermans</dc:creator>
<dc:creator>Caitlyn Vlasschaert</dc:creator>
<dc:creator>Victor Nauffal</dc:creator>
<dc:creator>So Mi Jemma Cho</dc:creator>
<dc:creator>Md Mesbah Uddin</dc:creator>
<dc:creator>Tetsushi Nakao</dc:creator>
<dc:creator>Abhishek Niroula</dc:creator>
<dc:creator>Marcus D R Klarqvist</dc:creator>
<dc:creator>Lachelle D Weeks</dc:creator>
<dc:creator>Amy E Lin</dc:creator>
<dc:creator>Seyedmohammad Saadatagah</dc:creator>
<dc:creator>Kim Lannery</dc:creator>
<dc:creator>Megan Wong</dc:creator>
<dc:creator>Whitney Hornsby</dc:creator>
<dc:creator>Steven A Lubitz</dc:creator>
<dc:creator>Christie Ballantyne</dc:creator>
<dc:creator>Siddhartha Jaiswal</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Benjamin L Ebert</dc:creator>
<dc:creator>Alexander G Bick</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias</dc:title>
<dc:identifier>pmid:37952204</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad670</dc:identifier>
</item>
<item>
<title>Bag-Valve-Mask Ventilation and Survival from Out-of-Hospital Cardiac Arrest: A Multicenter Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Background: Few studies have measured ventilation during early cardiopulmonary resuscitation (CPR) before advanced airway placement. Resuscitation guidelines recommend pauses after every 30 chest compressions to deliver ventilations. The effectiveness of bag-valve-mask ventilation delivered during the pause in chest compressions is unknown. We sought to determine: (1) the incidence of lung inflation with bag-valve-mask ventilation during 30:2 CPR; and (2) the association of ventilation with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.065561. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Few studies have measured ventilation during early cardiopulmonary resuscitation (CPR) before advanced airway placement. Resuscitation guidelines recommend pauses after every 30 chest compressions to deliver ventilations. The effectiveness of bag-valve-mask ventilation delivered during the pause in chest compressions is unknown. We sought to determine: (1) the incidence of lung inflation with bag-valve-mask ventilation during 30:2 CPR; and (2) the association of ventilation with outcomes after out-of-hospital cardiac arrest. <b>Methods:</b> We studied patients with out-of-hospital cardiac arrest from 6 sites of the Resuscitation Outcomes Consortium CCC study (Trial of Continuous Compressions versus Standard CPR in Patients with Out-of-Hospital Cardiac Arrest). We analyzed patients assigned to the 30:2 CPR arm with ≥2 minutes of thoracic bioimpedance signal recorded with a cardiac defibrillator/monitor. Detectable ventilation waveforms were defined as having a bioimpedance amplitude ≥0.5 Ω (corresponding to ≥250 mL V<sub>T</sub> ) and a duration ≥1 s. We defined a chest compression pause as a 3- to 15-s break in chest compressions. We compared the incidence of ventilation and outcomes in 2 groups: patients with ventilation waveforms in &lt;50% of pauses (group 1) versus those with waveforms in ≥50% of pauses (group 2). <b>Results:</b> Among 1976 patients, the mean age was 65 years; 66% were male. From the start of chest compressions until advanced airway placement, mean±SD duration of 30:2 CPR was 9.8±4.9 minutes. During this period, we identified 26861 pauses in chest compressions; 60% of patients had ventilation waveforms in &lt;50% of pauses (group 1, n=1177), and 40% had waveforms in ≥50% of pauses (group 2, n=799). Group 1 had a median of 12 pauses and 2 ventilations per patient versus group 2, which had 12 pauses and 12 ventilations per patient. Group 2 had higher rates of prehospital return of spontaneous circulation (40.7% versus 25.2%; <i>P</i>&lt;0.0001), survival to hospital discharge (13.5% versus 4.1%; <i>P</i>&lt;0.0001), and survival with favorable neurological outcome (10.6% versus 2.4%; <i>P</i>&lt;0.0001). These associations persisted after adjustment for confounders. <b>Conclusions:</b> In this study, lung inflation occurred infrequently with bag-valve-mask ventilation during 30:2 CPR. Lung inflation in ≥50% of pauses was associated with improved return of spontaneous circulation, survival, and survival with favorable neurological outcome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952192</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065561>10.1161/CIRCULATIONAHA.123.065561</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952192</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ahamed H Idris</dc:creator>
<dc:creator>Elisabete Aramendi Ecenarro</dc:creator>
<dc:creator>Brian Leroux</dc:creator>
<dc:creator>Xabier Jaureguibeitia</dc:creator>
<dc:creator>Betty Y Yang</dc:creator>
<dc:creator>Sarah Shaver</dc:creator>
<dc:creator>Mary P Chang</dc:creator>
<dc:creator>Tom Rea</dc:creator>
<dc:creator>Peter Kudenchuk</dc:creator>
<dc:creator>Jim Christenson</dc:creator>
<dc:creator>Christian Vaillancourt</dc:creator>
<dc:creator>Clifton W Callaway</dc:creator>
<dc:creator>David Salcido</dc:creator>
<dc:creator>Jonas Carson</dc:creator>
<dc:creator>Jennifer Blackwood</dc:creator>
<dc:creator>Henry E Wang</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Bag-Valve-Mask Ventilation and Survival from Out-of-Hospital Cardiac Arrest: A Multicenter Study</dc:title>
<dc:identifier>pmid:37952192</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065561</dc:identifier>
</item>
<item>
<title>Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Background: Device-detected atrial fibrillation (AF) (also known as subclinical AF or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke. Whether oral anticoagulation is effective and safe in this patient population is unclear. Methods: We performed a systematic review of MEDLINE and Embase for randomized trials comparing oral anticoagulation to antiplatelet or no antithrombotic therapy in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067512. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Device-detected atrial fibrillation (AF) (also known as subclinical AF or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke. Whether oral anticoagulation is effective and safe in this patient population is unclear. <b>Methods:</b> We performed a systematic review of MEDLINE and Embase for randomized trials comparing oral anticoagulation to antiplatelet or no antithrombotic therapy in adults with device-detected AF recorded by a pacemaker, implantable cardioverter-defibrillator, cardiac resynchronization therapy device or implanted cardiac monitor. We used random-effects models for meta-analysis and rated the quality of evidence using the GRADE framework. The review was pre-registered (PROSPERO CRD42023463212). <b>Results:</b> From 785 unique citations, we identified two randomized trials with relevant clinical outcome data; NOAH-AFNET 6 (2,536 participants) evaluated edoxaban and ARTESiA (4,012 participants) evaluated apixaban. Meta-analysis demonstrated that oral anticoagulation with these agents reduced ischemic stroke (relative risk [RR] 0.68, 95% confidence interval [CI] 0.50-0.92; high-quality evidence). The results from the two trials were consistent (I<sup>2</sup> statistic for heterogeneity=0%). Oral anticoagulation also reduced a composite of cardiovascular death, all-cause stroke, peripheral arterial embolism, myocardial infarction or pulmonary embolism (RR 0.85, 95% CI 0.73-1.00, I<sup>2</sup>=0%; moderate-quality evidence). There was no reduction in cardiovascular death (RR 0.95, 95% CI 0.76-1.17, I<sup>2</sup>=0%; moderate-quality evidence) or all-cause mortality (RR 1.08, 95% CI 0.96-1.21 I<sup>2</sup>=0%; moderate-quality evidence). Oral anticoagulation increased major bleeding (RR 1.62, 95% CI 1.05-2.5 I<sup>²</sup>=61%; high-quality evidence). <b>Conclusions:</b> The results of the NOAH-AFNET 6 and ARTESiA trials are consistent with each other. Meta-analysis of these two large randomized trials provides high-quality evidence that oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected AF and increases the risk of major bleeding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952187</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067512>10.1161/CIRCULATIONAHA.123.067512</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952187</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>William F McIntyre</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Nina Becher</dc:creator>
<dc:creator>Jeffrey S Healey</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Lena Rivard</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:creator>Andreas Goette</dc:creator>
<dc:creator>Antonia Zapf</dc:creator>
<dc:creator>Marco Alings</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials</dc:title>
<dc:identifier>pmid:37952187</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067512</dc:identifier>
</item>
<item>
<title>Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Background: Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight. This prespecified analysis investigated the effects of semaglutide on the primary and confirmatory secondary endpoints across the range of the Kansas...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067505. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight. This prespecified analysis investigated the effects of semaglutide on the primary and confirmatory secondary endpoints across the range of the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at baseline; and on all key summary and individual KCCQ domains. <b>Methods:</b> STEP-HFpEF randomized 529 participants with symptomatic HF, EF ≥45% and BMI of ≥30 kg/m<sup>2</sup> to once-weekly semaglutide 2.4 mg or placebo for 52 weeks. Dual primary endpoints were change in KCCQ-Clinical Summary Score (CSS) and body weight. Confirmatory secondary endpoints included change in 6-minute-walk-distance (6MWD), a hierarchical composite endpoint (death, HF events and change in KCCQ-CSS and 6MWD) and change in C-reactive protein. Patients were stratified by KCCQ-CSS tertiles at baseline. Semaglutide effects on the primary, confirmatory secondary and select exploratory endpoints (NTproBNP) were examined across these subgroups. Semaglutide effects on additional KCCQ domains (Total Symptom Score [including symptom burden and frequency], Physical Limitations Score, Social Limitations Score, Quality of Life Score, and Overall Summary Score) were also evaluated. <b>Results:</b> Baseline median KCCQ-CSS across tertiles was 37, 59 and 77 points, respectively. Semaglutide consistently improved primary endpoints across KCCQ tertiles 1-3 (estimated treatment differences (ETD;95% CI): for KCCQ-CSS, 10.7 (5.4,16.1), 8.1 (2.7,13.4), 4.6 (-0.6,9.9) points; for body weight, -11 (-13.2,-8.8), -9.4 (-11.5,-7.2), -11.8 (-14.0,-9.6)%, respectively; P<i>interaction</i>=0.28 and 0.29, respectively); same was observed for, confirmatory secondary and exploratory endpoints (P<i>interaction</i>>;0.1 for all). Semaglutide-treated patients experienced improvements in all key KCCQ domains (ETD: 6.7-9.6 points across domains; <i>P</i>≤0.001 for all). Greater proportion of semaglutide- versus placebo-treated patients experienced at least 5-, 10-, 15- and 20-point improvements in all KCCQ domains (Odds Ratios: 1.6-2.9 across domains; <i>P</i>&lt;0.05 for all). <b>Conclusions:</b> In patients with HFpEF and obesity, semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight and NTproBNP regardless of baseline health status. Benefits of semaglutide extended to all key KCCQ domains.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952180</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067505>10.1161/CIRCULATIONAHA.123.067505</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952180</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Melanie J Davies</dc:creator>
<dc:creator>Thomas Jon Jensen</dc:creator>
<dc:creator>Søren Rasmussen</dc:creator>
<dc:creator>Peter Erlang Marstrand</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Hiroshi Ito</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Vojtěch Melenovský</dc:creator>
<dc:creator>Walter Abhayaratna</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial</dc:title>
<dc:identifier>pmid:37952180</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067505</dc:identifier>
</item>
<item>
<title>Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952176/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF or HFpEF treated with dapagliflozin, an initial eGFR decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that SGLT2is should not be interrupted or discontinued in response to an initial eGFR decline.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 12. doi: 10.1001/jamacardio.2023.4664. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: An initial decline in estimated glomerular filtration rate (eGFR) is expected after initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed across patients with diabetes, chronic kidney disease, and heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the implications of initial changes in eGFR among patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis of the results of the DELIVER randomized clinical trial, which was an international multicenter study of patients with EF greater than 40% and eGFR greater than or equal to 25. The DELIVER trial took place from August 2018 to March 2022. Data for the current prespecified study were analyzed from February to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Dapagliflozin, 10 mg per day, or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: In this prespecified analysis, the frequency of an initial eGFR decline (baseline to month 1) was compared between dapagliflozin and placebo. Cox models adjusted for baseline eGFR and established prognostic factors were fit to estimate the association of an initial eGFR decline with cardiovascular (cardiovascular death or heart failure event) and kidney (≥50% eGFR decline, eGFR&lt;15 or dialysis, death from kidney causes) outcomes, landmarked at month 1, stratified by diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Study data from 5788 participants (mean [SD] age, 72 [10] years; 3253 male [56%]) were analyzed. The median (IQR) change in eGFR level from baseline to month 1 was -1 (-6 to 5) with placebo and -4 (-9 to 1) with dapagliflozin (difference, -3; P &lt; .001). A higher proportion of patients assigned to dapagliflozin developed an initial eGFR decline greater than 10% vs placebo (1144 of 2892 [40%] vs 737 of 2896 [25%]; odds ratio, 1.9; 95% CI, 1.7-2.1; P difference &lt;.001). An initial eGFR decline of greater than 10% (vs ≤10%) was associated with a higher risk of the primary cardiovascular outcome among those randomized to placebo (adjusted hazard ratio [aHR], 1.33; 95% CI, 1.10-1.62) but not among those randomized to dapagliflozin (aHR, 0.90; 95% CI, 0.74-1.09; P for interaction = .01). Similar associations were observed when alternative thresholds of initial eGFR decline were considered and when analyzed as a continuous measure. An initial eGFR decline of greater than 10% was not associated with adverse subsequent kidney composite outcomes in dapagliflozin-treated patients (aHR, 0.94; 95% CI, 0.49-1.82).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF or HFpEF treated with dapagliflozin, an initial eGFR decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that SGLT2is should not be interrupted or discontinued in response to an initial eGFR decline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952176/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952176</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4664>10.1001/jamacardio.2023.4664</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952176</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Akshay Desai</dc:creator>
<dc:creator>Pardeep Jhund</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe Martinez</dc:creator>
<dc:creator>Jose F Kerr Saraiva</dc:creator>
<dc:creator>Martina M McGrath</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Anna Maria Langkilde</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37952176</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4664</dc:identifier>
</item>
<item>
<title>Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: There was an alarming increase in cardiovascular hospitalizations among younger adults in the US from 2008 to 2019, and disparities between those residing in low- and higher-income communities did not narrow.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 11:ehad772. doi: 10.1093/eurheartj/ehad772. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Declines in cardiovascular mortality have stagnated in the United States since 2011. There is growing concern that these patterns reflect worsening cardiovascular health in younger adults. However, little is known about how the burden of acute cardiovascular hospitalizations and mortality have changed in this population. Changes in cardiovascular hospitalizations and mortality among adults aged 25-64 years were evaluated, overall and by community-level income.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the National Inpatient Sample, age-standardized annual hospitalization and inhospital mortality rates for acute myocardial infarction (AMI), heart failure, and ischemic stroke were determined among adults aged 25-64 years. Quasi-Poisson and quasi-binominal regression models were fitted to compare outcomes between individuals residing in low- and higher-income communities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between 2008 and 2019, age-standardized hospitalization rates for AMI increased among younger adults from 155.0 (95% CI 154.6, 155.4) per 100,000 to 160.7 (160.3, 161.1) per 100,000 (absolute change +5.7 [5.0, 6.3], p&lt;0.001). Heart failure hospitalizations also increased (165.3 [164.8, 165.7] to 225.3 [224.8, 225.8], absolute change +60.0 (59.3, 60.6), p&lt;0.001), as ischemic stroke hospitalizations (76.3 [76.1, 76.7] to 108.1 [107.8, 108.5], absolute change +31.7 (31.2, 32.2), p&lt;0.001). Across all conditions, hospitalizations rates were significantly higher among younger adults residing in low-income compared with higher-income communities, and disparities did not narrow between groups. In-hospital mortality decreased for all conditions over the study period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: There was an alarming increase in cardiovascular hospitalizations among younger adults in the US from 2008 to 2019, and disparities between those residing in low- and higher-income communities did not narrow.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952173</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad772>10.1093/eurheartj/ehad772</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952173</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Chantal M Henry</dc:creator>
<dc:creator>Andrew S Oseran</dc:creator>
<dc:creator>ZhaoNian Zheng</dc:creator>
<dc:creator>Huaying Dong</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States</dc:title>
<dc:identifier>pmid:37952173</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad772</dc:identifier>
</item>
<item>
<title>'Hard and Fast' Resuscitation Guidelines May Need a Bit of 'Breathing' Room</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37952160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.066071. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37952160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37952160</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066071>10.1161/CIRCULATIONAHA.123.066071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37952160</guid>
<pubDate>Sun, 12 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Michael Christopher Kurz</dc:creator>
<dc:date>2023-11-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>'Hard and Fast' Resuscitation Guidelines May Need a Bit of 'Breathing' Room</dc:title>
<dc:identifier>pmid:37952160</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066071</dc:identifier>
</item>
<item>
<title>Germinal centers output clonally diverse plasma cell populations expressing high- and low-affinity antibodies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37951212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Germinal centers (GCs) form in lymph nodes after immunization or infection to facilitate antibody affinity maturation and memory and plasma cell (PC) development. PC differentiation is thought to involve stringent selection for GC B cells expressing the highest-affinity antigen receptors, but how this plays out during complex polyclonal responses is unclear. We combine temporal lineage tracing with antibody characterization to gain a snapshot of PCs developing during influenza infection. GCs...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 7:S0092-8674(23)01173-X. doi: 10.1016/j.cell.2023.10.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Germinal centers (GCs) form in lymph nodes after immunization or infection to facilitate antibody affinity maturation and memory and plasma cell (PC) development. PC differentiation is thought to involve stringent selection for GC B cells expressing the highest-affinity antigen receptors, but how this plays out during complex polyclonal responses is unclear. We combine temporal lineage tracing with antibody characterization to gain a snapshot of PCs developing during influenza infection. GCs co-mature B cell clones with antibody affinities spanning multiple orders of magnitude; however, each generates PCs with similar efficiencies, including weak binders. Within lineages, PC selection is not restricted to variants with the highest-affinity antibodies. Differentiation is commonly associated with proliferative expansion to produce "nodes" of identical PCs. Immunization-induced GCs generate fewer PCs but still of low- and high-antibody affinities. We propose that generating low-affinity antibody PCs reflects an evolutionary compromise to facilitate diverse serum antibody responses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37951212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37951212</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.022>10.1016/j.cell.2023.10.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37951212</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Adrien Sprumont</dc:creator>
<dc:creator>Ana Rodrigues</dc:creator>
<dc:creator>Simon J McGowan</dc:creator>
<dc:creator>Colin Bannard</dc:creator>
<dc:creator>Oliver Bannard</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Germinal centers output clonally diverse plasma cell populations expressing high- and low-affinity antibodies</dc:title>
<dc:identifier>pmid:37951212</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.022</dc:identifier>
</item>
<item>
<title>A Complex Anterior Mediastinal Mass in a Young Adult</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067585. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37950914</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067585>10.1161/CIRCULATIONAHA.123.067585</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950914</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Giselle Alexandra Suero-Abreu</dc:creator>
<dc:creator>Lily Sung</dc:creator>
<dc:creator>Anushri Parakh</dc:creator>
<dc:creator>Brian Ghoshhajra</dc:creator>
<dc:creator>Tomas G Neilan</dc:creator>
<dc:creator>Doreen DeFaria Yeh</dc:creator>
<dc:creator>Yin P Hung</dc:creator>
<dc:creator>Danielle B Cameron</dc:creator>
<dc:creator>Jordan P Bloom</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Complex Anterior Mediastinal Mass in a Young Adult</dc:title>
<dc:identifier>pmid:37950914</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067585</dc:identifier>
</item>
<item>
<title>Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113131019&amp;v=2.17.9.post6+86293ac
      <description>Background: Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. Methods: In this prospective, randomized, open-label, blinded endpoint trial, in a single...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067597. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. <b>Methods:</b> In this prospective, randomized, open-label, blinded endpoint trial, in a single UK hospital, 220 women were randomly assigned 1:1 to self-monitoring with research physician-optimized antihypertensive titration, or usual postnatal care from primary care physician and midwife. Participants were aged 18 years or over, with pre-eclampsia or gestational hypertension, requiring antihypertensives on hospital discharge postnatally. Pre-specified secondary cardiac imaging outcomes were recorded by echocardiography around delivery, and again at blood pressure primary outcome assessment, around nine months postpartum, when cardiovascular magnetic resonance was also performed. <b>Results:</b> 187 women (101 intervention; 86 usual care) underwent echocardiography at baseline and follow up, at a mean 258+/-14.6 days postpartum, of which 174 (93 intervention; 81 usual care) also had cardiovascular magnetic resonance at follow up. Relative wall thickness by echocardiography was 0.06 (95% CI0.07 to 0.05, P=&lt;0.001) lower in the intervention group between baseline and follow up, and cardiovascular magnetic resonance at follow up demonstrated a lower left ventricular mass (-6.37g/m<sup>2</sup> (95% CI -7.99 to -4.74, P&lt;0.001), end diastolic volume (-3.87ml/m<sup>2</sup>, 95% CI -6.77 to -0.98, P=0.009) and end systolic volume (-3.25ml/m<sup>2</sup>, 95% CI 4.87 to -1.63, P &lt;0.001) and higher left and right ventricular ejection fraction by 2.6% (95% CI 1.3 to 3.9, P&lt;0.001) and 2.8% (95% CI 1.4 to 4.1, P&lt;0.001) respectively. Echocardiography assessed left ventricular diastolic function demonstrated a mean difference in average E/E' of 0.52 (95% CI -0.97 to -0.07, P=0.024), and a reduction in left atrial volumes of -4.33ml/m<sup>2</sup> (95% CI -5.52 to -3.21, P=&lt;0.001) between baseline and follow up, when adjusted for baseline differences in measures. <b>Conclusions:</b> Short-term postnatal optimization of blood pressure control following hypertensive pregnancy, through self-monitoring and physician-guided antihypertensive titration, associates with long term changes in cardiovascular structure and function, in a pattern associated with more favorable cardiovascular outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113131019&v=2.17.9.post6+86293ac">37950907</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067597>10.1161/CIRCULATIONAHA.123.067597</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950907</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jamie Kitt</dc:creator>
<dc:creator>Samuel Krasner</dc:creator>
<dc:creator>Logan Barr</dc:creator>
<dc:creator>Annabelle Frost</dc:creator>
<dc:creator>Katherine Tucker</dc:creator>
<dc:creator>Paul A Bateman</dc:creator>
<dc:creator>Katie Suriano</dc:creator>
<dc:creator>Yvonne Kenworthy</dc:creator>
<dc:creator>Winok Lapidaire</dc:creator>
<dc:creator>Miriam Lacharie</dc:creator>
<dc:creator>Rebecca Mills</dc:creator>
<dc:creator>Cristian Roman</dc:creator>
<dc:creator>Lucy Mackillop</dc:creator>
<dc:creator>Alexandra Cairns</dc:creator>
<dc:creator>Christina Aye</dc:creator>
<dc:creator>Vanessa Ferreira</dc:creator>
<dc:creator>Stefan Piechnik</dc:creator>
<dc:creator>Elena Lukaschuk</dc:creator>
<dc:creator>Basky Thilaganathan</dc:creator>
<dc:creator>Lucy C Chappell</dc:creator>
<dc:creator>Adam J Lewandowski</dc:creator>
<dc:creator>Richard J McManus</dc:creator>
<dc:creator>Paul Leeson</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</dc:title>
<dc:identifier>pmid:37950907</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067597</dc:identifier>
</item>





























</channel>
</rss>